Core Insights - A total of 22 financing events were disclosed on June 20, 2025, involving 15 domestic companies and 7 foreign companies, with a total financing amount of approximately 14.189 billion RMB [2] - The enterprise service sector had the highest number of financing events, while the smart technology sector had the highest financing amount [2] - In the healthcare sector, there were 5 financing events involving 3 domestic companies and 2 foreign companies, totaling approximately 1.138 billion RMB [2] Domestic Healthcare Sector - Three domestic healthcare companies received funding, totaling approximately 1.074 billion RMB: - Zhejiang Taide Pharmaceutical completed a 10 million USD Pre-IPO financing, with investors including Weiguang Venture Capital and Shiyao Group [2] - United Imaging Intelligence completed a 1 billion RMB Series A financing, ranking first in all Series A financing this year [2] - Beijian Testing completed a 10 million RMB Series A financing, focusing on biosafety and animal laboratories [2] Foreign Healthcare Sector - Two foreign healthcare companies received funding, totaling approximately 64 million RMB: - SerImmune completed an 8 million USD Series A financing, ranking in the top 50 for Series A financing this year [3] - Droplet IV completed a 2 million USD seed round financing [3]

Summary of Key Points Core Viewpoint - The report highlights a total of 28 financing events disclosed on June 5, 2025, involving 16 domestic companies and 12 foreign companies, with a total financing amount of approximately 12.38 billion RMB. The healthcare sector leads in the number of events, while the automotive sector leads in financing amount. Group 1: Domestic Healthcare Sector - The domestic healthcare sector saw 4 companies receiving funding, totaling approximately 1.92 billion RMB [1] - Kelun-Biotech received a strategic investment of 250 million USD, ranking in the top 10% of all strategic investments this year [1] - Qiyu Biotech completed a C round financing of several hundred million RMB, with the investor being Yifeng Capital [1] - Ruizhou Biotech secured A+ round financing of several tens of millions RMB, ranking in the top 50% of all A+ round financings this year [1] - Sipure completed an angel round financing of 200 million RMB, ranking in the top 1% of all angel round financings this year [1] Group 2: Foreign Healthcare Sector - The foreign healthcare sector reported 2 companies being acquired and 1 company receiving funding, totaling approximately 410 million RMB [2] - Focal Medical was acquired by Continuity Biosciences, a US-based biopharmaceutical service provider [2] - Biocrates Life Sciences was acquired by Bruker, an Australian analytical reagent kit developer [2] - Holoeyes completed B+ round financing of 1.6 million USD, focusing on VR organ model technology [2]